Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | FPR2 | P25090 | 1/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.50 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.50 |
| ▸ | REN | P00797 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16124030 | 1.00 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAKMT2A | |
| SCHEMBL12062761 | 1.00 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAKMT2A | |
| SCHEMBL16228288 | 1.00 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAKMT2A | |
| SCHEMBL16228734 | 1.00 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAKMT2A | |
| SCHEMBL16228287 | 1.00 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAKMT2A | |
| SCHEMBL16463914 | 0.91 | KLK5 (0.53) | ITGB3ITGA2BPPARGPPARAMMP1 | |
| SCHEMBL16463916 | 0.91 | KLK5 (0.53) | ITGB3ITGA2BPPARGPPARAMMP1 | |
| SCHEMBL335309 | 0.90 | ITGB3 (0.67) | ITGB3ITGA2BPPARGPPARAKMT2A | |
| SCHEMBL335310 | 0.90 | ITGB3 (0.67) | ITGB3ITGA2BPPARGPPARAKMT2A | |
| SCHEMBL1308867 | 0.90 | ITGB3 (0.67) | ITGB3ITGA2BPPARGPPARAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657058-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150353601-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-8765745-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8735441-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8431571-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8080576-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080545-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144648-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7691852-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20070293465-A1 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353601-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | ITGB3 4755/4885ITGA2B 4671/4885PPARG 4475/4885 |
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | ITGB3 4755/4885ITGA2B 4671/4885PPARG 4475/4885 |
| US-20070293465-A1 | Compounds for enzyme inhibition | PSME1, PSMB1, PSME3 | ITGB3 4755/4885ITGA2B 4671/4885PPARG 4475/4885 |
| US-20100144648-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | ITGB3 4755/4885ITGA2B 4671/4885PPARG 4475/4885 |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | ITGB3 4755/4885ITGA2B 4671/4885PPARG 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.